Analysed ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) News Sources
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
25-03-2026
yahoo.com
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
19-03-2026
yahoo.com
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
12-03-2026
yahoo.com
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
11-02-2026
yahoo.com
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully
09-02-2026
yahoo.com
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
05-02-2026
yahoo.com
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
21-01-2026
yahoo.com
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
16-01-2026
yahoo.com
What is the current price of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)?
The current price of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) is $5.31.
ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) since the previous trading day is $0.37.
ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) since the previous trading day is 7.4899%.
What is the most recent average sentiment score for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)?
The most recent average sentiment score for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)?
The most recent sentiment for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) is .
SEC-8K** Filing Available For ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.